Baxter Appoints New Chief Medical and Scientific Officers

TL;DR

Baxter just hired a new CMO and CSO. Big moves for R&D.

AI Summary

Baxter International Inc. announced on November 18, 2024, changes in its executive leadership. The company appointed Dr. John T. "Jay" Davies as Chief Medical Officer and Dr. Laura J. V. Johnson as Chief Scientific Officer, effective November 18, 2024. These appointments are part of the company's ongoing efforts to strengthen its leadership team.

Why It Matters

The appointment of new medical and scientific leaders can signal a strategic shift or renewed focus on innovation and product development within Baxter International.

Risk Assessment

Risk Level: low — The filing concerns routine executive appointments and does not indicate any significant financial or operational risks.

Key Players & Entities

• Baxter International Inc. (company) — Registrant
• Dr. John T. "Jay" Davies (person) — Appointed Chief Medical Officer
• Dr. Laura J. V. Johnson (person) — Appointed Chief Scientific Officer
• November 18, 2024 (date) — Effective date of appointments

FAQ

Key Financial Figures

• $1.00 — ange on which registered Common Stock, $1.00 par value BAX (NYSE) New York Stock Exc

Filing Documents

• bax-20241118.htm (8-K) — 26KB
• 0001628280-24-049002.txt ( ) — 208KB
• bax-20241118.xsd (EX-101.SCH) — 3KB
• bax-20241118_def.xml (EX-101.DEF) — 18KB
• bax-20241118_lab.xml (EX-101.LAB) — 31KB
• bax-20241118_pre.xml (EX-101.PRE) — 18KB
• bax-20241118_htm.xml (XML) — 6KB

From the Filing

bax-20241118 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 18, 2024 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission File Number) (I.R.S. Employer Identification No.) One Baxter Parkway , Deerfield , Illinois 60015 (Address of principal executive offices) (Zip Code) ( 224 ) 948-2000 (Registrant's telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $1.00 par value BAX (NYSE) New York Stock Exchange NYSE Chicago 1.3% Global Notes due 2025 BAX 25 New York Stock Exchange 1.3% Global Notes due 2029 BAX 29 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter): Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act: Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 18, 2024, Mr. Peter M. Wilver notified Baxter International Inc. (the "Company") of his resignation from the Board of Directors of the Company (the "Board") and the Audit Committee and Compensation and Human Capital Committee thereof, effective December 31, 2024. Mr. Wilver has indicated that his departure from the Board was for personal reasons and is not the result of any disagreement with management, including with respect to the Company's operations, policies or practices. Upon the effectiveness of Mr. Wilver's resignation, the number of directors constituting the Board shall automatically decrease to 11 directors. Further, Mr. Jeffrey A. Craig, a current director and member of the Board's Audit Committee, will become the chairperson of the Audit Committee upon the effectiveness of Mr. Wilver's resignation. Mr. Craig is the former Chief Executive Officer and President of Meritor, Inc. ("Meritor"), having held various positions with Meritor between 2006 and 2021. Before that time, Mr. Craig was President and CEO of various divisions of General Motors Acceptance Corp. ("GMAC"), including its Commercial Finance organization and Business Credit division. He joined GMAC after serving as an audit partner with Deloitte & Touche LLP. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: November 22, 2024 BAXTER INTERNATIONAL INC. By: /s/ Ellen K. Bradford Name: Ellen K. Bradford Title: Senior Vice President and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR